These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 17596807

  • 1. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine.
    Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A.
    Pediatr Infect Dis J; 2007 Jul; 26(7):632-8. PubMed ID: 17596807
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P, Lim FS, Han HH, Willems P.
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P.
    Vaccine; 2009 Jan 14; 27(3):446-53. PubMed ID: 19007835
    [Abstract] [Full Text] [Related]

  • 8. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR, Black S, Kuter BJ.
    J Infect Dis; 2008 Mar 01; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella.
    Ramet J.
    Int J Infect Dis; 2007 Nov 01; 11 Suppl 2():S49-55. PubMed ID: 18162247
    [Abstract] [Full Text] [Related]

  • 12. Assessing the introduction of universal varicella vaccination in the Netherlands.
    Boot HJ, de Melker HE, Stolk EA, de Wit GA, Kimman TG.
    Vaccine; 2006 Sep 11; 24(37-39):6288-99. PubMed ID: 16790302
    [Abstract] [Full Text] [Related]

  • 13. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine.
    Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP).
    MMWR Morb Mortal Wkly Rep; 2008 Mar 14; 57(10):258-60. PubMed ID: 18340332
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, Descamps D, Willems P.
    Pediatr Infect Dis J; 2006 Jan 14; 25(1):12-8. PubMed ID: 16395096
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, Douha M, Willems P.
    Eur J Pediatr; 2012 Mar 14; 171(3):463-70. PubMed ID: 21935584
    [Abstract] [Full Text] [Related]

  • 18. A combination vaccine against measles, mumps, rubella and varicella.
    Knuf M, Faber J, Barth I, Habermehl P.
    Drugs Today (Barc); 2008 Apr 14; 44(4):279-92. PubMed ID: 18536786
    [Abstract] [Full Text] [Related]

  • 19. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schödel F, Gress JO, Kuter BJ, Protocol 014 Study Group for ProQuad.
    Pediatrics; 2006 Feb 14; 117(2):265-72. PubMed ID: 16452343
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.
    Gatchalian S, Leboulleux D, Desauziers E, Bermal N, Borja-Tabora C.
    Southeast Asian J Trop Med Public Health; 2003 Sep 14; 34(3):589-97. PubMed ID: 15115135
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.